HAVCR1 and neoplasm: We speculate that TIM-1, a new costimulatory candidate molecule for tumor treatment, not only directly enhances the antitumor effect of CD8+ T cells and NK cells but also changes the tumor microenvironment to induce more effective antitumor immune response.